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Summary
Background: Stopping nucleos(t)ide analogues (NA) after hepatitis B e antigen (HBeAg)
seroconversion is associated with high relapse rates in Asian patients, but data in Caucasian
cohorts are scarce. Clinical course, outcomes and immunological aspects of chronic hepatitis
B infections differ substantially between distinct ethnicities.
Aim: The aim of this study was to determine relapse rates, factors predicting relapse and clini-
cal outcomes after nucleos(t)ide analogue cessation in a large, predominantly Caucasian cohort
of chronic hepatitis B patients with nucleos(t)ide analogue-induced HBeAg seroconversion.
Methods: This is a nationwide observational cohort study including HBeAg positive, mono-
infected chronic hepatitis B patients with nucleos(t)ide analogue-induced HBeAg seroconver-
sion from 18 centres in Belgium.
Results: A total of 98 patients with nucleo(s)tide analogue-induced HBeAg seroconversion
were included in the study. Of the 62 patients who stopped treatment after a median con-
solidation treatment of 8 months, 30 relapsed. Higher gamma-glutamyl transferase levels at
both treatment initiation (HR 1.004; P = 0.001 per unit increment) and HBeAg seroconver-
sion (HR 1.006; P = 0.013 per unit increment) were associated with an increased risk of clin-
ically significant relapse in a multivariate Cox regression model. Treatment cessation led to
liver-related death in 2 patients, of whom one showed a severe flare. Of the patients who
continued treatment after HBeAg seroconversion, none relapsed or developed severe hep-
atic outcomes.
Conclusion: Treatment withdrawal in Caucasian chronic hepatitis B patients after nucleos
(t)ide analogue-induced HBeAg seroconversion results in viral relapses in more than half of
patients with potential fatal outcomes. These real-world data further lend support to prefer-
entially continue NA treatment after HBeAg seroconversion until HBsAg loss.
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1 | BACKGROUND
Chronic hepatitis B virus (HBV) infections are a major global health
problem, affecting 250 million people worldwide.1,2 Clinical presenta-
tion remains often subclinical for decades, but serious liver-related
complications and liver-related death develop in one-fourth of all
untreated patients.1,3 Standard oral treatment consists of nucleos(t)
ide analogues (NA) and suppresses, but does not eradicate the virus.
Hepatitis B e antigen (HBeAg) seroconversion is an important land-
mark during the natural disease course of a chronic HBV infection and
is used to monitor NA treatment efficiency. It is associated with an
improved immune control of the HBV and marks the transition from a
HBeAg-positive hepatitis phase to a HBeAg-negative chronic infection
state with limited risk of further disease progression.4-6
It remains controversial whether NA treatment can be stopped
after NA-induced HBeAg seroconversion, as relapse rates of up to
50% have been observed.7-9 This is reflected by contrasting recom-
mendations of the 3 major international scientific hepatological asso-
ciations: Asian guidelines recommend to stop treatment after HBeAg
seroconversion, whereas American and European guidelines favour
treatment continuation, but allow discontinuation in selected
patients with close subsequent monitoring.5,10,11 Several factors such
as longer consolidation therapy and lower hepatitis B surface antigen
(HBsAg) and HBV DNA levels at treatment cessation have previously
been linked to a decreased chance of relapse. A recent meta-analysis
could, however, not substantiate these associations.12 In addition,
there is currently little evidence of the effect of treatment cessation
after HBeAg seroconversion on liver-related outcomes such as hepa-
tocellular carcinoma, liver decompensation and cirrhosis.11,13,14
So far published studies assessing the clinical consequences of
NA treatment stop after HBeAg seroconversion mainly focus on
Asian patients.12 However, it is well appreciated that the host’s
ethnicity influences HBV’s natural history and immune responses.4,15
Asian patients show, for example, lower spontaneous or treatment-
induced HBsAg seroclearance rates, and have higher HBV relapse
rates in HBeAg-negative patients after treatment cessation.16 Clini-
cal hepatocellular carcinoma risk scores developed in Asian cohorts
seem to be unreliable in Caucasian and especially African patients,
the latter developing hepatocellular carcinoma at much younger
ages.17,18 Firm associations of immune-related gene polymorphisms
with HBV persistence, seroconversion, seroclearance and disease
progression vary between ethnicities. For example, the HLA-DR
polymorphism rs 9277535 (550 A/G) is strongly associated with
chronic hepatitis B and its outcomes in Asian, but not in
African-American or Caucasian patients.19,20 In addition, Asian and
Caucasian patients have different HBV-related T-cell epitopes.21 It
therefore remains to be determined whether HBV relapse rates,
factors predicting relapse and clinical outcomes after NA cessation
are similar in Caucasian and Asian patients. These data are,
however, difficult to obtain, given the practice of NA continuation
after HBeAg seroconversion in most European countries and the
USA.5,11
In contrast to most national guidelines on HBV in Europe, the
Belgian HBV reimbursement criteria impose to stop NA treatment
after 6 months consolidation therapy following HBeAg seroconver-
sion. This makes Belgium a unique country to investigate the out-
come after NA cessation following HBeAg seroconversion in
Caucasian patients.22 We investigated relapse rates, factors predict-
ing clinically significant relapse and clinical outcomes after NA treat-
ment stop in a nationwide multicentre study.
2 | METHODS
2.1 | Study design
We retrospectively included chronic HBeAg-positive HBV-infected
patients with NA-induced HBeAg seroconversion between 1998 and
2016 from 18 centres in Belgium. Patients were followed at the out-
patient hepatology clinics every 3-6 months according to the interna-
tional treatment guidelines applicable at that time. Exclusion criteria
were concomitant infection with the hepatitis C virus (HCV), hepatitis
delta virus (HDV) and/or human immunodeficiency virus (HIV) and the
long-term use (>2 weeks) of immunosuppressive therapy up to
6 months before NA therapy was initiated. The study was approved
by the ethical committees of the Antwerp University Hospital and par-
ticipating centres (no. EC15/44/464) in November 2015.
2.2 | Data collection
HBeAg-positive patients were included consecutively from the avail-
ability of electronic medical records onwards. All patient charts were
individually analysed (n = 2090) for NA-use (n = 533) and subse-
quent NA-induced HBeAg seroconversion (n = 115). HBeAg sero-
conversion and HBsAg loss/seroconversion were defined as the loss
of HBeAg or HBsAg and the appearance of anti-HBeAg and anti-
HBsAg antibodies on two occasions, respectively, at least 1 month
apart. Consolidation therapy was defined as the time between
HBeAg seroconversion and treatment stop. Belgian NA reimburse-
ment criteria impose to stop antiviral therapy 6 months after HBeAg
seroconversion. However, some patients stopped treatment before
the end of a 6-month consolidation therapy, either at their own ini-
tiative or at the discretion of the treating physician. Other patients
continued treatment beyond 6 months after HBeAg seroconversion,
either because the treating physician asked for an exception to the
prevailing reimbursement criteria or because the patient was
included in a NA clinical trial or medical need programme. For cir-
rhotic patients, antiviral treatment with lamivudine is reimbursed
since 2010 irrespective of alanine aminotransferase (ALT) levels,
HBeAg seroconversion and HBV viral load. This implicates that treat-
ment continuation in cirrhotic patients after HBeAg seroconversion
was not reimbursed between 2002 and 2010.
Data on demographics (date of birth, gender, ethnicity), biochem-
istry (ALT, aspartate aminotransferase [AST], gamma-glutamyl trans-
ferase, alkaline phosphatases [ALP]), virology (HBeAg and HBsAg
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status, HBV viral load, HCV, HDV and HIV status), previous treat-
ment type (interferon/lamivudine/adefovir/entecavir/tenofovir) and
duration, fibrosis stage and liver disease severity were collected sys-
tematically in one case report form per patient.
Fibrosis was assessed histologically using the Metavir score on
pre-treatment liver biopsies in 92.5% of the patients. The Belgian
reimbursement criteria for HBV treatment require a liver biopsy prior
to treatment start, except for patients with haemophilia or concomi-
tant anticoagulant use. Laboratory tests were performed by the local
or tertiary referral centres of the NA stop study group. Viral load, sero-
logical assays and biochemical parameters were measured using stan-
dardised automated methods. The upper limit of normal (ULN) for ALT
was defined as 40 IU/mL. The limit of quantification for HBV DNA
varied between 20 and 357 IU/mL depending on the time of determi-
nation (2009 and later vs 1998). Positive HBV DNA values but below
the limit of quantification were given the arbitrary value of the lowest
limit of quantification. Results indicating HBV DNA levels below the
limit of detection (“Negative”) were coded as 0.
2.3 | Clinical outcomes
Virologic relapse was defined as a single elevation of HBV DNA
>2000 IU/mL. Combined relapse included ALT levels >2 9 ULN (bio-
chemical relapse) and virologic relapse. Relapse was considered per-
sistent if detected consecutively on two or more occasions at least
3 months apart. Relapse was considered clinically significant if per-
sistent or if immediate retreatment was deemed necessary by the
treating physician. Sustained response was defined as persistent
HBV DNA <2000 IU/mL after treatment stop. HBeAg reversion was
defined as the reappearance of HBeAg. Both HBsAg loss and HBeAg
reversion had to be confirmed on two consecutive samples at least
1 month apart. Hepatic decompensation was defined as the pres-
ence of variceal bleeding, ascites and/or encephalopathy. The diag-
nosis of hepatocellular carcinoma and cirrhosis was made according
to international guidelines.23
2.4 | Statistical analysis
The date of treatment cessation was defined as baseline. Predictive
factors for clinically significant relapse were calculated using a Cox
proportional hazard regression model. Follow-up time was calculated
as time from baseline to the first date of relapse detection or loss-
to-follow-up (LTFU) or HBsAg loss. Cumulative rates of clinically sig-
nificant relapse were plotted on a Kaplan-Meier curve. A Receiver
Operating Characteristics (ROC) curve was applied to assess the dis-
criminatory power of predictive factors for clinically significant
relapse. Continuous data were presented as Mean  SD or median
(interquartile range [IQR]). A Mann-Whitney U test, student t test or
one-way ANOVA was used to compare continuous variables,
whereas a chi-squared test was used to compare categorical vari-
ables between two groups. Data were analysed in SPSS version 23.0
(SPSS, Chicago, IL, USA) All statistical tests were two-sided and
P < 0.05 was considered statistically significant.
3 | RESULTS
3.1 | Patient characteristics
Of 2090 identified HBeAg-positive patients, 533 fulfilled the NA
treatment reimbursement criteria and subsequently started NA treat-
ment during the inclusion period (1998-2016). 356/533 had a HBV
mono-infection and were not taking immunosuppressive drugs (see
Figure 1). Confirmed NA-induced HBeAg seroconversion was
observed in 115/356 (32%) patients after a median treatment dura-
tion of 17.7 months (IQR 9.7-32.4). Nine patients showed simultane-
ous HBsAg loss. Eight patients were LTFU immediately after
treatment stop and were therefore excluded (Figure 1). The analysed
cohort thus consisted of 98 predominantly male (75%) patients of
mostly Caucasian (68%) origin with a median follow-up duration of
5.8 years (IQR 3.1-9.9) after treatment start. Treatment was stopped
in 62/98 patients after a median consolidation therapy of 8.0 (IQR
4.6-14.9) months and was continued in 36/98 patients upon the dis-
cretion of the treating physician. An overview of all patient charac-
teristics after HBeAg seroconversion is depicted in Table 1. The
continuous treatment group consisted of more cirrhotic patients
(39% vs 18%; P = 0.028) and had a shorter follow-up time (median
2.1 years vs 5.3 years; P < 0.001) after HBeAg seroconversion than
the NA stop group. There was no difference in time to HBeAg sero-
conversion (median 18.8 vs 14.2 months; P = 0.916) between both
groups.
3.2 | Relapse rates
During a median follow-up time of 3.8 years (IQR 1.6-7.0) after
treatment stop, 30/62 patients (48.3%) relapsed of whom 16
showed only a virologic and 14 a combined virologic and biochemi-
cal relapse. Relapse was transient in 7 patients, persistent in 10
patients and another 13 patients were retreated after a single
relapse detection (HBV DNA elevation >2000 IU/mL). The cumula-
tive rate of clinically significant relapse (either persistent relapse or
immediately retreated relapse) was 31%, 45%, 51%, 51%, 58% and
63% after 1, 2, 3, 4, 5 and 6 years, respectively, with 33, 24, 16, 14,
12 and 8 patients still in follow-up and event-free at the respective
time points (Figure 2).
Twenty relapsed patients started retreatment (4 lamivudine, 12
tenofovir, 1 adefovir, 3 entecavir) with subsequent complete viral
DNA suppression in all. Three patients showed persistent virologic
relapse without ALT-rise and were therefore not retreated. Two more
patients in the sustained response group were retreated proactively
due to a HBV DNA rise <2000 IU/mL, despite having normal ALT
levels and were therefore considered to be sustained responders.
Demographic and treatment-related characteristics were similar
between patients irrespective of their virologic outcome after NA
stop (Table 2). Similarly, there was no difference in HBV DNA levels
at treatment start and HBeAg seroconversion. At treatment start
and cessation, however, higher ALT levels were noted in patients
going on to develop transient flares (P = 0.010). One patient in the
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transient relapse group stopped therapy at his own initiative without
HBV DNA suppression <2000 IU/mL, resulting in a transient peak
HBV DNA flare of 4.16 log IU/mL, but with subsequent virus control
<2000 IU/mL. There was no difference in peak HBV DNA (Mean
6.74  2.08 log IU/mL vs 6.64  1.40 log IU/mL; P = 0.998) and
peak ALT (median 2.8 ULN vs 2.5 ULN; P = 0.980) after treatment
stop between patients who developed a persistent relapse and those
who were immediately retreated, indicating that the decision of the
treating physician to immediately restart treatment was justified
(Table 2). Patients with a persistent relapse showed a milder onset
of relapse as compared to those in need of immediate retreatment,
but the final severity of relapse was not different between the per-
sistent relapse group and the immediate retreatment group (Table 2).
As the clinical relapse severity did not differ between both groups,
they were combined in further statistical modelling to predict clini-
cally significant relapse rates.24 A total of 6 noncirrhotic patients
showed HBeAg reversion within 1 year after treatment cessation.
This was accompanied by combined virologic and biochemical
relapse. No relapse was detected in the group who continued treat-
ment after HBeAg seroconversion.
3.3 | Factors predicting clinically significant relapse
Factors assessed for predicting clinically significant relapse in an
univariate cox regression model are depicted in Table 3. Among
HBsAg+, HBeAg+ patients
between 1998 and 2016
(n = 2090)
NA treatment (n = 533)
Excluded: No NA treatment
(n = 1557)
Excluded: HIV+, HCV+, HDV+ or long-term
immunosupression (n = 177)
Excluded: no HBeAg
seroconversion (n = 241)
HBeAg seroconversion
(n = 115)
Excluded: simultaneous
HBsAg loss or LTFU after
HBsAg SC (n = 9)
Treatment stopped (n = 70)
Follow-up after treatment
stop (n = 62)
Excluded: LTFU immediately
after treatment stop (n = 8)
Treatment continued (n = 36)
F IGURE 1 Flowchart of the patients
included in the study. NA, nucleos(t)ide
analogues; HBsAg, hepatitis B surface
antigen; HBeAg, hepatitis B e antigen; SC,
seroconversion; HIV, human
immunodeficiency virus; HDV, hepatitis
delta virus; HCV, hepatitis C virus; LTFU,
loss-to-follow-up
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F IGURE 2 Cumulative rates of clinically significant relapse after
treatment cessation. *Clinically significant = persistent or
immediately retreated relapse
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those, only gamma-GT levels at start of treatment (HR 1.004;
P = 0.001 per unit increment) and at HBeAg seroconversion (HR
1.006; P = 0.014 per unit increment), but not at treatment stop
(HR 1.004; P = 0.083 per unit increment), were predictive of clini-
cally significant relapse (Table 3). Gamma-GT levels at HBeAg sero-
conversion (Table 3) and treatment start (not shown) remained
significantly associated with clinically significant relapse when cor-
rected for age in multivariate cox regression models. Of the 9
patients with a gamma-GT <14 IU/mL at HBeAg seroconversion,
none relapsed within 2 years after treatment cessation. Patients
with a gamma-GT above 50 IU/mL at HBeAg seroconversion
(n = 13) had a 75% chance of clinically significant relapse within
2 years after treatment cessation. Relapse and subsequent
retreatment was observed in 7 patients with gamma-GT >50 IU/mL
at HBeAg seroconversion in our cohort. None of the patients men-
tioned excessive alcohol use (>10 Units/week). A ROC curve (Fig-
ure S1) showed an area under the curve (AUC) of 0.613 for
gamma-GT at HBeAg seroconversion, indicating a moderate dis-
criminatory power to predict clinically significant HBV relapse. No
other factors were significantly related to the risk of clinically sig-
nificant relapse, except for gamma-GT to platelet ratio (GPR), a
non-invasive fibrosis marker, at treatment start (Table 3). When
corrected for gamma-GT levels at treatment start in a multivariate
cox regression model, only gamma-GT at treatment start
(P = 0.025) remained predictive of clinically significant relapse.
Overall, this suggests that the association of gamma-GT levels at
TABLE 1 Patient characteristics grouped per treatment status after HBeAg seroconversion
NA stopped (n = 62) NA continued (n = 36) P-value
Male gender (n) 45 (73%) 30 (83%) 0.210
Previous interferon treatment (n) 18 (29%) 12 (33%) 0.660
Ethnicity
Asian 11 7 0.947
African 7 5
Caucasian 43 24
Other 1 0
HBeAg seroconversion
Agea (y) 42.9  16.9 43.2  17.5 0.924
ALTb (ULN) 0.8 (0.6-1.0) 0.9 (0.6-1.5) 0.126
HBV DNAa (10log) 1.57  1.12 1.55  1.22 0.963
Gamma-GTb (IU/mL) 22 (16-50) 35 (18-68) 0.721
Treatment at HBeAg seroconversion
Lamivudine 28 9 0.569
Tenofovir 9 18
Adefovir 7 3
Entecavir 14 6
Lamivudine + Adefovir 4 0
Time to HBeAg seroconversion (mo)b 18.8 (10.1-28.6) 14.2 (6.1-28.3) 0.916
FU-time post-HBeAg seroconversion (mo)b 64.1 (28.0-100.6) 24.7 (12.2-49.0) <0.001
FU-time post-treatment stop (mo)b 46.4 (19.7-85.3) /
Start of treatment
ALTb (ULN) 2.8 (2.0-5.1) 4.0 (1.7-8.1) 0.407
HBV DNAa (10log) 6.91  1.63 6.92  1.81 0.950
Presence of cirrhosis (n) 11 (18%) 14 (39%) 0.028
Gamma-GTb (IU/mL) 53 (23-98) 70 (48-192) 0.205
Histological fibrosis at start of treatment
Metavir F0-F1 18 8 0.215
Metavir F2 19 7
Metavir F3-F4 21 17
Continuous variables were compared using a student t test, categorical variables using a Chi-squared test.
ULN, Upper Limit of Normal (40 IU/mL); SC, Seroconversion; NA, nucleos(t)ide Analogues: /, not applicable; FU, follow-up; ALT, alanine aminotrans-
ferase; FU, follow-up; HBV, hepatitis B virus.
aMean  SD.
bMedian (IQR).
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HBeAg seroconversion or treatment start with clinically significant
relapse is independent of liver fibrosis.
3.4 | Clinical outcomes
Of the 14 cirrhotic patients in the continuous treatment group, 3
had an episode of ascites, respectively, 1.3, 0.5 months before and
0.4 months after HBeAg seroconversion, but all recovered. Of the
patients who stopped treatment, two developed severe hepatic out-
comes leading to liver-related death: one patient with histological
fibrosis grade Metavir F2-F3 at start of treatment developed a sev-
ere hepatitis flare 6 months after tenofovir treatment cessation and
subsequently died due to a spontaneous bacterial peritonitis and
septic shock. Another patient with biopsy-proven cirrhosis at start of
treatment developed a multifocal hepatocellular carcinoma 10 years
after adefovir treatment cessation. Both patients did not show any
concomitant risk factors for liver disease.
4 | DISCUSSION
In the present study, we investigated the long-term clinical conse-
quences of stopping NA after HBeAg seroconversion in a chronic
hepatitis B cohort consisting of 69% (43/62) Caucasian patients.
TABLE 2 Patient and treatment-related characteristics according to the outcome after treatment stop
Sustained response
(n = 32)
Transient relapse
(n = 7)
Persistent relapse
(n = 10)
Immediate retreatment
(n = 13) P-value
General
Male gender 23 (71.9%) 5 (71.4%) 7 (70.0%) 10 (76.9%) 0.984
Caucasian ethnicity 24 (75.0%) 5 (71.4%) 5 (50.0%) 9 (69.2%) 0.538
Cirrhotic patients 5 (15.6%) 2 (28.6%) 1 (10.0%) 1 (7.6%) 0.695
Treatment at HBeAg SC 14 LAM, 4 TDF, 3 ADV,
9 ETV, 2 LAM+ADV
3 LAM,
3 ADV, 1 ETV
4 LAM, 2 TDF, 2 ETV,
2 LAM+ADV
7 LAM, 3 TDF,
1 ADV, 2 ETV
0.587
Age at HBeAg SC (y)a 43.53  17.99 42.71  18.38 43.50  16.76 41.15  15.10 0.979
Time to HBeAg SC (mo)b 12.0 (8.2-21.5) 26.4 (23.5-72.9) 24.7 (18.0-58.4) 13.6 (10.6-47.6) 0.018
Consolidation therapy (mo)b 7.5 (4.0-15.5) 14.7 (7.6-25.2) 7.1 (4.0-14.5) 7.8 (4.3-13.8) 0.473
Follow-up time after
treatment stop (mo)b
33.5 (15.4-82.3) 59.4 (20.2-79.1) 75.0 (21.5-96.5) 62.4 (29.6-114.9) 0.599
At treatment start
HBV DNA (10log IU/mL)a 7.23  1.75 5.89  1.37 7.14  1.50 6.55  1.46 0.202
ALT (ULN)b 2.8 (1.9-4.9) 7.8 (3.5-10.5) 2.4 (1.9-11.7) 2.5 (1.7-3.75) 0.019*
Gamma-GT (IU/mL)b 43 (19-73) 132 (51-190) 83 (37-169) 47 (23-198) 0.144
At HBeAg seroconversion
HBV DNA (10log IU/mL)a 1.41  1.29 1.77  1.34 1.65  0.85 1.98  0.79 0.753
ALT (ULN)b 0.8 (0.5-1.0) 0.7 (0.6-1.3) 0.8 (0.6-0.9) 0.9 (0.6-1.4) 0.885
Gamma-GT (IU/mL)b 19 (16-33) 50 (20-74) 28 (21-57) 27 (19-237) 0.067
AT treatment stop
HBV DNA (10log IU/mL)b 0.00 (0.00-2.55) 2.55 (1.99-3.22) 1.28 (0.00-1.30) 1.28 (0.83-2.65) 0.093
ALT (ULN)b 0.6 (0.5-0.8) 1.0 (0.6-1.1) 0.8 (0.7-1.0) 0.7 (0.6-1.0) 0.014*
Gamma-GT (IU/mL)b 19 (14-33) 35 (17-45) 21 (17-52) 29 (15-66) 0.214
Relapse
HBV DNA at first relapse
detection (10log IU/mL)
1.42  1.17 3.87  0.21 4.66  1.64 6.64  1.40 <0.001*
HBV DNA peak (10log IU/mL)a 1.42  1.17 3.87  0.21 6.74  2.08 6.64  1.40 <0.001*
ALT at first relapse detection (ULN)b 0.7 (0.5-1.0) 0.9 (0.5-2.5) 1.1 (0.9-1.5) 2.8 (1.6-11.4) <0.001*
ALT peak (ULN)b 0.7 (0.5-1.0) 0.9 (0.5-2.5) 2.5 (1.1-16.6) 2.8 (1.6-11.4) <0.001*
HBeAg reversion (n) 0 1 2 3 0.025
Characteristics were compared using a one-way ANOVA with, if *P < 0.05, a Tukey test to determine the origin of the significant values.
SC, seroconversion; ULN, upper limit of normal (40 IU/mL for ALT); LAM, lamivudine; TDF, tenofovir; ETV, entecavir; ADV, adefovir; ALT, alanine
aminotransferase; HBV, hepatitis B virus.
aMean  SD.
bMedian (IQR).
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Almost half (45%) of the patients showed signs of clinically signifi-
cant relapse within 2 years after treatment cessation (Figure 2). Two
of the stopped patients died due to liver-related death. To the best
of our knowledge, this is the largest study to date assessing the risk
of HBV relapse after treatment cessation in a cohort of chronic hep-
atitis B patients of mixed, but predominant Caucasian ethnicity.
No differences were observed between Caucasian and other
ethnicities in our cohort. Relapse rates (up to 63% 6 years after
treatment stop) are similar to those previously reported in Asian
cohorts, but higher than those generally reported after spontaneous
HBeAg seroconversion.9,12,24-26 In 234 Taiwanese patients, only
33.2% relapses were observed after spontaneous HBeAg serocon-
version during a median follow-up of 8.6 years.27 These results
were confirmed in a Caucasian study including 61 patients with
spontaneous HBeAg seroconversion, of whom only 21 (34%)
showed signs of relapse after a median follow-up of 22.8 years.28
In the present study, we further substantiate that NA-induced
HBeAg seroconversion is less durable than spontaneous HBeAg
seroconversion.
Several factors predictive for relapse after treatment cessation
have previously been suggested, but none of these factors proved to
be a reliable predictor in a recent meta-analysis, probably due to the
heterogeneity in relapse definitions used.12,16,29-31 In our study, we
aimed to identify factors predictive of clinically significant relapse,
defined as either persistent relapse or severe relapse with immediate
retreatment. The peak HBV DNA and ALT after treatment stop were
not different between both groups. In addition, peak HBV DNA
levels in the immediately retreated patients were higher than the
previously established cut-off of 5-log IU/mL HBV DNA to predict
the development of persistent relapse and clinical flare after NA
stop.24 From a clinical point of view, identifying patients who will
develop a persistent relapse and those who will develop an immedi-
ate severe relapse is highly relevant, as opposed to those developing
no or only transient relapses. We therefore combined the first two
groups in statistical modelling to predict clinically significant relapse,
which is in line with the methodological approach of a previously
published retrospective NA stop cohort study.16
Interestingly, in our cohort gamma-GT levels at HBeAg serocon-
version proved to be predictive of clinically significant relapse after
treatment cessation. Gamma-GT levels <14 IU/mL at treatment ces-
sation were 100% predictive of sustained remission after treatment
cessation and levels >50 IU/mL were associated with a 75% chance
of clinically significant relapse after treatment stop. None of the
patients with gamma-GT levels >50 IU/mL reported excessive alco-
hol use (>10 Units/week). However, the discriminatory value of
Gamma-GT is moderate (ROC curve: AUC = 0.613), indicating that
more factors are needed to reliably predict clinically significant
relapse after treatment cessation.
The pathogenetic basis for the association between Gamma-
GT levels and relapse is currently unclear. However, the biological
relevance of gamma-GT as a biomarker in overall disease outcome
and in particular in viral hepatitis has become increasingly substan-
tiated in recent years. Elevated gamma-GT levels are associated
with an increased overall mortality.32-36 They are associated with
treatment-induced HBeAg seroconversion in hepatitis B patients
and with sustained viral response after interferon treatment in
hepatitis C patients.35,37,38 In addition, gamma-GT levels have
been suggested to predict significant fibrosis in hepatitis B
patients.39 We carefully assessed the predictive value of FIB-4,
APRI, GPR and histological fibrosis stage. None of them were pre-
dictive of persistent relapse, suggesting that the underlying patho-
biological mechanism between the association of gamma-GT and
clinically significant relapse is not related to hepatic fibrosis. More
detailed studies are clearly indicated to unravel this mechanism as
well as to investigate the value of Gamma-GT as a prognostic fac-
tor for treatment stop.
In our cohort, we observed a fatal flare in a patient with base-
line histologically proven Metavir F2-F3 fibrosis. It is difficult to
ascertain whether there was an initial sampling error and baseline
cirrhosis or a true rapid disease progression after treatment cessa-
tion in this patient. Given a biopsy length of 11 mm with 7 portal
fields, an underlying cirrhosis seems possible.40 In addition, one
patient developed a multifocal hepatocellular carcinoma 10 years
after treatment cessation. Whether the observed tumour develop-
ment was the result of treatment cessation is hard to prove. How-
ever, previously published studies show that continuing NA
treatment is associated with an up to threefold lower risk of hepa-
tocellular carcinoma.41-43 International guidelines suggest not to
stop NA therapy in cirrhotic patients due to the risk for hepatic
decompensation.44 Lim et al previously reported two cases of fatal
reactivation when lamivudine therapy was stopped in start-of-treat-
ment HBeAg negative, cirrhotic patients.14 Another Asian study
reported one fatal hepatic decompensation after lamivudine with-
drawal following HBeAg seroconversion in a patient who was cir-
rhotic at start of therapy.13 The combination of fatal outcomes and
high relapse rates in our national cohort study urges for a re-eva-
luation of Belgian national treatment reimbursement policies. Cur-
rently, there are no uniform, validated markers to guide safe NA
stop after HBeAg seroconversion. Based on our findings, it would
seem prudent to only stop NA treatment in patients without fibro-
sis and—pending further studies—those with the lowest gamma-GT
levels at HBeAg seroconversion. In most HBeAg seroconverted
chronic hepatitis B patients, however, NA treatment should be con-
tinued until HBsAg loss.
This study has some limitations. First, while our study design is
intrinsically retrospective, the inclusion of hard biological or clinical
endpoints will have partly overcome this selection bias. Neverthe-
less, there were 11% LTFU patients after treatment stop, which may
have impacted our study results. Second, we were not able to evalu-
ate the predictive role of HBsAg levels and HBV genotype as these
parameters were not routinely measured in clinical practice. How-
ever, several studies suggest that HBV genotype would not influence
relapse rates after nucleos(t)ide analogue stop.12,45,46 Third—
although not substantiated by the virologic and biochemical relapse
profiles—we cannot firmly exclude that any of the immediately
retreated patients would be transient.
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TABLE 3 Univariate and multivariate Cox regression model to clinically significant relapse after treatment cessation
Univariate model to predict clinically significant relapse Adjusted, multivariate model
P HR (95% CI) P Adjusted HR (95% CI)
General
Ethnicity (Caucasian vs non-Caucasian) 0.804 1.112 (0.388-2.083)
Male gender 0.956 0.974 (0.381-2.492)
Previous interferon treatment 0.096 0.400 (0.136-1.178)
First vs second generation NA 0.375 0.680 (0.290-1.596)
Total treatment time (mo) 0.082 1.000 (1.000-1.001)
At treatment start
ALT (per unit) 0.519 0.999 (0.997-1.001)
AST (per unit) 0.784 1.000 (0.998-1.002)
Gamma-GT (per unit) 0.001 1.004 (1.002-1.007)
ALP (per unit) 0.077 1.003 (1.000-1.006)
Total bilirubin 0.708 0.875 (0.436-1.757)
HBV DNA (10log) 0.432 1.112 (0.853-1.450)
Platelets 0.855 0.999 (0.993-1.006)
Cirrhosis (yes or no) 0.242 0.417 (0.096-1.804)
Age 0.568 1.008 (0.982-1.034)
APRI 0.593 0.949 (0.784-1.149)
FIB-4 0.712 0.968 (0.813-1.152)
GPR 0.031 1.721 (1.051-2.818)
At HBeAg seroconversion
ALT (per unit) 0.474 0.994 (0.976-1.011)
AST (per unit) 0.907 0.998 (0.972-1.026)
Gamma-GT (per unit) 0.014 1.006 (1.001-1.010) 0.013 1.006 (1.001-1.010)
ALP (per unit) 0.552 1.002 (0.995-1.009)
Total bilirubin 0.730 1.029 (0.438-2.421)
HBV DNA (10log) 0.733 1.070 (0.725-1.580)
Platelets 0.875 1.001 (0.994-1.007)
APRI 0.652 0.795 (0.294-2.154)
FIB-4 0.698 0.929 (0.648-1.331)
GPR 0.185 1.542 (0.813-2.924)
Consolidation therapy duration (per month) 0.319 0.980 (0.941-1.020) 0.588 0.989 (0.949-1.030)
Age 0.392 1.011 (0.986-1.037) 0.457 0.987 (0.952-1.022)
At treatment stop
ALT (per unit) 0.897 1.001 (0.980-1.023)
AST (per unit) 0.473 1.015 (0.975-1.056)
Gamma-GT (per unit) 0.083 1.004 (0.999-1.009)
ALP (per unit) 0.447 1.003 (0.995-1.011)
Total bilirubin 0.702 0.774 (0.207-2.886)
HBV DNA (10log) 0.467 0.884 (0.636-1.231)
Undetectable HBV DNA (yes/no) 0.447 0.680 (0.252-1.836)
Platelets 0.908 1.000 (0.995-1.006)
APRI 0.750 0.784 (0.176-3.500)
FIB-4 0.801 0.948 (0.627-1.433)
GPR 0.247 1.543 (0.740-3.220)
Age 0.412 1.011 (0.985-1.037)
HR, hazard ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Gamma-GT, gamma-glutamyl transferase; ALP,
alkaline phosphatases; APRI, AST to platelet ratio index; FIB-4, fibrosis-4 score; GPR, gamma-GT to platelet ratio.
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In conclusion, stopping treatment after HBeAg seroconversion in
a large, predominant Caucasian population with long-term follow-up
led to high relapse rates with potential fatal outcome. Gamma-GT
levels at treatment start and at HBeAg seroconversion were predic-
tive for clinically significant relapse.
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